Compounds > triazolam
Page last updated: 2024-08-16

triazolam and gefitinib

triazolam has been researched along with gefitinib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Beijnen, JH; Rooswinkel, RW; Schinkel, AH; Sparidans, RW; van Herwaarden, AE; van Waterschoot, RA1

Reviews

1 review(s) available for triazolam and gefitinib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for triazolam and gefitinib

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Gefitinib; Humans; Hydroxylation; Intestines; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes; Quinazolines; Species Specificity; Substrate Specificity; Triazolam

2009